logo of Sinopharm Group (same as China National Pharmaceutical Group), with bilingual name on the right
|Traded as||SEHK: 01099 (H share)|
|Founder||China National Pharmaceutical Group|
|Headquarters||Sinopharm Plaza, Shanghai, China|
|Revenue||CN¥227.069 billion (2015)|
|CN¥9.169 billion (2015)|
|CN¥3.761 billion (2015)|
|Total assets||CN¥138.267 billion (2015)|
|Total equity||CN¥30.052 billion (2015)|
|Owner||Sinopharm Industrial Investment (56.79%)|
|Parent||Sinopharm Industrial Investment|
|Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards
|Sinopharm Group Co., Ltd.|
|Literal meaning||Sinopharm Holding Joint-Stock Limited Company|
|Literal meaning||Sinopharm Holding|
|Second alternative Chinese name|
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Sinopharm Group researches and develops, manufactures, distributes, and markets medicine and other healthcare products. Sinopharm Group manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
- "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016.
- "Sinopharm Group Co. Ltd.: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2017-07-27.
- China's Sinopharm gets OK for $1 bln HK IPO